Hormone Replacement Trial Against ALzheimers' Disease

Summary

The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid. The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy. Postmenopausal women with and without history of breast cancer will be recruited for the trial.

Interventions

• blood take · PROCEDURE

  Blood is taken to analyse degradation products of the metabolism of amyloid

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* postmenopausal women
* 40 - 65 years

Exclusion Criteria:

* Longer than 10 years in menopause
* thyroid dysfunction
* hypertension
* medical history of psychiatric comorbidity
* Alcohol and/or drug abuse
* medical history of neurologic symptoms with cognitive symptoms

Sites (1)

• Ghent university hospital, Ghent, Belgium · RECRUITING